A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Phase 2 Recruiting 200 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Timeline

Start: 2025-10-16
Primary completion: 2027-03
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eloralintide	Protein / enzyme biologic	—	Subcutaneous
Subject	Macupatide	Protein / enzyme biologic	—	Subcutaneous

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Summary

Timeline

Drugs

Indications